Oligoastrocytoma pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 13: Line 13:
*Development of oligoastrocytoma is the result of multiple [[mutation|genetic mutations]].
*Development of oligoastrocytoma is the result of multiple [[mutation|genetic mutations]].
*Oligoastrocytomas are mixed tumors that have overlapping molecular genetics with both [[oligodendrogliomas]] and [[astrocytomas]].<ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref>
*Oligoastrocytomas are mixed tumors that have overlapping molecular genetics with both [[oligodendrogliomas]] and [[astrocytomas]].<ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref>
*30-70% of oligoastrocytomas show loss of heterozygosity (LOH) of [[chromosome 1|1p]] and [[chromosome 19|19q]].<ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref>
*Genes associated with the pathogenesis of oligoastrocytoma and anaplastic oligoastrocytoma include:<ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref><ref name="pmid25143301">{{cite journal| author=Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S et al.| title=Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. | journal=Acta Neuropathol | year= 2014 | volume= 128 | issue= 4 | pages= 551-9 | pmid=25143301 | doi=10.1007/s00401-014-1326-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25143301  }} </ref><ref name="pmid18507036">{{cite journal| author=Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F et al.| title=Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. | journal=Anticancer Res | year= 2008 | volume= 28 | issue= 2A | pages= 913-20 | pmid=18507036 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18507036  }} </ref><ref name="pmid12006525">{{cite journal| author=Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR et al.| title=Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. | journal=Clin Cancer Res | year= 2002 | volume= 8 | issue= 5 | pages= 1100-6 | pmid=12006525 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12006525  }} </ref><ref name="pmid23948976">{{cite journal| author=van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG et al.| title=MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. | journal=Clin Cancer Res | year= 2013 | volume= 19 | issue= 19 | pages= 5513-22 | pmid=23948976 | doi=10.1158/1078-0432.CCR-13-1157 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23948976  }} </ref><ref name="pmid22869205">{{cite journal| author=Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF et al.| title=Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. | journal=Oncotarget | year= 2012 | volume= 3 | issue= 7 | pages= 709-22 | pmid=22869205 | doi= | pmc=PMC3443254 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22869205  }} </ref><ref name="pmid16018821">{{cite journal| author=Liang Y, Bollen AW, Nicholas MK, Gupta N| title=Id4 and FABP7 are preferentially expressed in cells with astrocytic features in oligodendrogliomas and oligoastrocytomas. | journal=BMC Clin Pathol | year= 2005 | volume= 5 | issue=  | pages= 6 | pmid=16018821 | doi=10.1186/1472-6890-5-6 | pmc=PMC1182359 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16018821  }} </ref>
*Genes associated with the pathogenesis of oligoastrocytoma and anaplastic oligoastrocytoma include:<ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref><ref name="pmid25143301">{{cite journal| author=Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S et al.| title=Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. | journal=Acta Neuropathol | year= 2014 | volume= 128 | issue= 4 | pages= 551-9 | pmid=25143301 | doi=10.1007/s00401-014-1326-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25143301  }} </ref><ref name="pmid18507036">{{cite journal| author=Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F et al.| title=Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. | journal=Anticancer Res | year= 2008 | volume= 28 | issue= 2A | pages= 913-20 | pmid=18507036 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18507036  }} </ref><ref name="pmid12006525">{{cite journal| author=Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR et al.| title=Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. | journal=Clin Cancer Res | year= 2002 | volume= 8 | issue= 5 | pages= 1100-6 | pmid=12006525 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12006525  }} </ref><ref name="pmid23948976">{{cite journal| author=van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG et al.| title=MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. | journal=Clin Cancer Res | year= 2013 | volume= 19 | issue= 19 | pages= 5513-22 | pmid=23948976 | doi=10.1158/1078-0432.CCR-13-1157 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23948976  }} </ref><ref name="pmid22869205">{{cite journal| author=Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF et al.| title=Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. | journal=Oncotarget | year= 2012 | volume= 3 | issue= 7 | pages= 709-22 | pmid=22869205 | doi= | pmc=PMC3443254 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22869205  }} </ref><ref name="pmid16018821">{{cite journal| author=Liang Y, Bollen AW, Nicholas MK, Gupta N| title=Id4 and FABP7 are preferentially expressed in cells with astrocytic features in oligodendrogliomas and oligoastrocytomas. | journal=BMC Clin Pathol | year= 2005 | volume= 5 | issue=  | pages= 6 | pmid=16018821 | doi=10.1186/1472-6890-5-6 | pmc=PMC1182359 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16018821  }} </ref>
:*''[[Isocitrate dehydrogenase|IDH1]]''
:*''[[Isocitrate dehydrogenase|IDH1]]''
Line 23: Line 24:
:*''CIC''
:*''CIC''
:*''[[Far upstream element-binding protein 1|FUBP1]]''
:*''[[Far upstream element-binding protein 1|FUBP1]]''
*30-70% of oligoastrocytomas show loss of heterozygosity (LOH) [[chromosome 1|1p]] and [[chromosome 19|19q]].<ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref>


===Gross Pathology===
===Gross Pathology===

Revision as of 19:35, 20 October 2015

Oligoastrocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligoastrocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oligoastrocytoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oligoastrocytoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oligoastrocytoma pathophysiology

CDC on Oligoastrocytoma pathophysiology

Oligoastrocytoma pathophysiology in the news

Blogs on Oligoastrocytoma pathophysiology

Directions to Hospitals Treating Glioma

Risk calculators and risk factors for Oligoastrocytoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

Pathophysiology

Pathogenesis

Genetics

  • Development of oligoastrocytoma is the result of multiple genetic mutations.
  • Oligoastrocytomas are mixed tumors that have overlapping molecular genetics with both oligodendrogliomas and astrocytomas.[3]
  • 30-70% of oligoastrocytomas show loss of heterozygosity (LOH) of 1p and 19q.[3]
  • Genes associated with the pathogenesis of oligoastrocytoma and anaplastic oligoastrocytoma include:[3][4][5][6][7][8][9]

Gross Pathology

Microscopic Pathology

On microscopic histopathological analysis, oligoastrocytoma is characterized by:[13][14][15][16][17]

  • Highly cellular lesion composed of both oligodendroglial and astrocytic components
  • Two types of pattern: biphasic and diffuse
    • Biphasic pattern demonstrates oligodendroglial and astrocytic differentiation, whereas diffuse pattern demonstrates intermingling of both the components
  • Oligodendrocytes
  • Astrocytes
    • Star-shaped cells
    • Composed of gemistocytes
    • Multinucleated giant cells
    • Ovoid nucleus
    • Nuclear atypia

On microscopic histopathological analysis, anaplastic oligoastrocytoma is characterized by:[13][14][15]

Gallery

  • Biopsy specimen of an oligoastrocytoma (HE stain).[18]

    Biopsy specimen of an oligoastrocytoma (HE stain).[18]

Immunohistochemistry

Oligoastrocytoma is demonstrated by positivity to tumor markers such as:[19][20][9][21]

Gallery

  • Histology of oligoastrocytoma cells demonstrating positivity to tumor marker GFAP.[22]

    Histology of oligoastrocytoma cells demonstrating positivity to tumor marker GFAP.[22]

  • Histology of oligoastrocytoma cells demonstrating positivity to tumor marker Ki-67.[23]

    Histology of oligoastrocytoma cells demonstrating positivity to tumor marker Ki-67.[23]

References

  1. ↑ Introduction of oligodendroglioma and oligoastrocytoma. American Brain Tumor Association. http://www.abta.org/secure/oligodendrioma-oligo.pdf. Accessed on October 16, 2015
  2. ↑ Mixed Gliomas. Canadian ?Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on#ixzz3okGrTzyi. Accessed on October 16, 2015
  3. ↑ 3.0 3.1 3.2 3.3 Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J; et al. (2002). "Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets". Am J Pathol. 161 (1): 313–9. doi:10.1016/S0002-9440(10)64183-1. PMC 1850690. PMID 12107116.
  4. ↑ Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S; et al. (2014). "Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma". Acta Neuropathol. 128 (4): 551–9. doi:10.1007/s00401-014-1326-7. PMID 25143301.
  5. ↑ Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F; et al. (2008). "Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas". Anticancer Res. 28 (2A): 913–20. PMID 18507036.
  6. ↑ Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR; et al. (2002). "Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival". Clin Cancer Res. 8 (5): 1100–6. PMID 12006525.
  7. ↑ van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG; et al. (2013). "MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951". Clin Cancer Res. 19 (19): 5513–22. doi:10.1158/1078-0432.CCR-13-1157. PMID 23948976.
  8. ↑ Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF; et al. (2012). "Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas". Oncotarget. 3 (7): 709–22. PMC 3443254. PMID 22869205.
  9. ↑ 9.0 9.1 Liang Y, Bollen AW, Nicholas MK, Gupta N (2005). "Id4 and FABP7 are preferentially expressed in cells with astrocytic features in oligodendrogliomas and oligoastrocytomas". BMC Clin Pathol. 5: 6. doi:10.1186/1472-6890-5-6. PMC 1182359. PMID 16018821.
  10. ↑ Location of oligoastrocytoma. Dr. Bruno Di Muzio and Dr. Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/oligoastrocytoma. Accessed on October 19, 2015
  11. ↑ Shimizu T, Saito N, Aihara M, Kurihara H, Nakazato Y, Ueki K; et al. (2004). "Primary spinal oligoastrocytoma: a case report". Surg Neurol. 61 (1): 77–81, discussion 81. PMID 14706386.
  12. ↑ Oligoastrocytoma. Wikipedia 2015. https://en.wikipedia.org/wiki/Oligoastrocytoma. Accessed on October 20, 2015
  13. ↑ 13.0 13.1 Pathology of oligoastrocytoma. Dr Bruno Di Muzio and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/oligoastrocytoma. Accessed on October 16, 2015
  14. ↑ 14.0 14.1 Naugle DK, Duncan TD, Grice GP (2004). "Oligoastrocytoma". Radiographics. 24 (2): 598–600. doi:10.1148/rg.242035069. PMID 15026604.
  15. ↑ 15.0 15.1 Pathology of oligoastrocytoma. Wikipedia 2015. https://en.wikipedia.org/wiki/Oligoastrocytoma. Accessed on October 16, 2015
  16. ↑ Love, S.; Loius, D. & Ellison, D.W. (2008), Greenfield's neuropathology, 1 (8th ed.), Boca Raton, Florida: Hodder Arnold
  17. ↑ Histology of anaplastic oligoastrocytes. Dr. Frank Gaillard. Radiopaedia 2015. http://radiopaedia.org/cases/anaplastic-oligoastrocytoma. Accessed on October 19, 2015
  18. ↑ Classification and external sources of oligoastrocytoma. Wikipedia 2015. https://en.wikipedia.org/wiki/Oligoastrocytoma. Accessed on October 20, 2015
  19. ↑ IHC of oligoastrocytoma. Librepathology 2015. http://librepathology.org/wiki/index.php/Oligoastrocytoma. Accessed on October 16, 2015
  20. ↑ Kolenda-Roberts HM, Harris N, Singletary E, Hardisty JF (2013). "Immunohistochemical characterization of spontaneous and acrylonitrile-induced brain tumors in the rat". Toxicol Pathol. 41 (1): 98–108. doi:10.1177/0192623312452492. PMID 22821367.
  21. ↑ Grier, J. T. (2006). "Low-Grade Gliomas in Adults". The Oncologist. 11 (6): 681–693. doi:10.1634/theoncologist.11-6-681. ISSN 1083-7159.
  22. ↑ Image courtesy of Dr. Frank Gaillard. Radiopaedia (original file here). Creative Commons BY-SA-NC
  23. ↑ Image courtesy of Dr. Frank Gaillard. Radiopaedia (original file here). Creative Commons BY-SA-NC


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Oligoastrocytoma_pathophysiology&oldid=1177617"